Compare Las Vegas Sands Corp. (LVS) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs Travere Therapeutics Inc. Common Stock — how do they compare? Las Vegas Sands Corp. trades at $36.94 (market cap $23.99B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Las Vegas Sands Corp. is far larger — about 4.8× Travere Therapeutics Inc. Common Stock's market cap, and Las Vegas Sands Corp. pays a 3.24% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Las Vegas Sands Corp. for 73 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| LVS | TVTX | |
|---|---|---|
Market Cap | $23.99B | $5.02B |
Volume | 5,076,550 | 2,060,842 |
Sector | Consumer Cyclical | Health |
52-Week High | $69.49 | $67.52 |
52-Week Low | $35.81 | $26.79 |
Typical Hold Time | 73 Days | 0 Days |
Enterprise Value | $35.88B | $5.15B |
Dividend Yield | 3.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LVS trades at $37.04, up 2.46% today, amid a bearish technical signal. The company reported revenue of $13.02B in 2025 with a net income margin of 12.59%, and recent earnings show mixed results with a Q2 2026 miss. Analysts maintain a strong buy consensus with a $58.89 price target, indicating significant upside potential. Recent news highlights Sands China's community initiatives and operational milestones, reinforcing its market presence.
The outlook for LVS is positive based on solid fundamentals and analyst optimism, but risks include high debt levels and market volatility. Investment opportunity lies in the valuation discount relative to growth prospects, though investors should monitor earnings consistency and macroeconomic factors affecting the gaming and hospitality sector.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
